02522-A: The Investigation of Lypoxigenase-5 Expression in Canine Normal, Hyperplastic and Neoplastic Urinary Bladder Epithelium

Grant Status: Closed

Grant Amount: $5,000
Riccardo Finotello, DVM, PhD; University of Liverpool
March 1, 2018 - November 30, 2018

Sponsor(s):

Breed(s): -All Dogs
Research Program Area: Oncology
Donate to Support this Research Program Area

Abstract

Transitional Cell Carcinoma (TCC) is the most common tumor of the canine urinary tract, causing nonresolving urinary signs (i.e., straining, hematuria) after it invades a large portion of the bladder and/or neighboring structures. Surgery may not be an option and chemotherapy represents the most common treatment; however, significant tumor reduction rarely occurs, resulting in a poor long-term outcome. Piroxicam, a non-steroidal anti-inflammatory drug, is one of the most effective compounds used to slow TCC progression. Piroxicam may also potentiate the effect of conventional chemotherapeutics, which are largely unrewarding when administered alone. Piroxicam targets cyclooxygenases (COX; proinflammatory enzymes), constitutively expressed by the bladder (COX-1) and overexpressed by the cancer (COX-2). Other inflammatory markers such as Lipoxigenase-5 (LOX-5) have been investigated in human TCCs, and found to be overexpressed compared to normal tissue. Importantly, in vitro studies have revealed that treating cancer cells with LOX-5 inhibitors can lead to 30% tumor reduction. The investigators will evaluate the expression of LOX-5 in canine TCCs, cystitis and normal bladder samples. COX-1&2 expression will be also analyzed in relationship to LOX-5. The demonstration of LOX-5 expression in canine TCC would open the possibility of using lipoxygenase inhibitors together with cyclooxygenase inhibitors to provide better treatment strategies for dogs. These inhibitors are safe and have shown stronger anti-inflammatory effect than piroxicam alone in dogs with other inflammatory disorders including uveitis and osteoarthritis.

Publication(s)

Finotello, R., Schiavo, L., Ressel, L., Frohmader, A., Silvestrini, P., & Verin, R. (2019). Lipoxygenase-5 Expression in Canine Urinary Bladder: Normal Urothelium, Cystitis and Transitional Cell Carcinoma. Journal of Comparative Pathology, 170, 1–9. https://doi.org/10.1016/j.jcpa.2019.05.001

Help Future Generations of Dogs

Participate in canine health research by providing samples or by enrolling in a clinical trial. Samples are needed from healthy dogs and dogs affected by specific diseases.

Learn How to Help

Get Canine Health News:
Please leave this field empty
American Kennel Club Canine Health Foundation, Inc

8051 Arco Corporate Dr.
Suite 300
Raleigh, NC 27617
(888)-682-9696

Tax ID# 13-3813813

  

© 2021 AKC Canine Health Foundation | Privacy Policy | Site Map

Site by Blackbaud, Inc.